GLP-1 Receptor Agonist Updates for Cardiometabolic Health Research

Explore the impact of GLP-1 receptor agonists on cardiometabolic health and their role in managing related conditions.

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I present a clinically grounded, first-person overview of the close relationship between type 2 diabetes and heart failure, and how modern therapeutics—especially SGLT2 inhibitors and GLP-1 receptor agonists—are reshaping outcomes across the heart, kidney, and metabolic domains. I explain the physiologic underpinnings that bind diabetes to heart failure, the mechanistic rationale for SGLT2 and GLP-1 therapies, and landmark results that inform current guidelines. I also show how our multidisciplinary practice at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas integrates chiropractic care, functional medicine, rehabilitation, and personal injury services under the medical direction of Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), who brings over 40 years of internal medicine experience. You will see how integrative chiropractic and rehabilitative approaches complement cardiometabolic therapy to improve function, reduce hospitalizations, protect kidneys, and enhance quality of life. I include case-informed protocols and clinical observations from my platforms at sciatica.clinic and my LinkedIn profile.

Our Multidisciplinary Model in El Paso: Internal Medicine Direction Meets Integrative Chiropractic Care

In our clinic, I practice within a team-based, integrative framework—a common model in injury and integrative clinics—where an MD provides medical direction alongside a chiropractor to unite pharmacotherapy with non-pharmacologic strategies.

• Maria Guadalupe Cardenas, MD: Medical Director and Collaborative Physician, Board Certified in Internal Medicine (NPI #1164426749; Texas MD License #J2933), providing guideline-aligned cardiometabolic care, diagnostics, risk stratification, and medication oversight with more than 40 years of experience.
• Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST: Integrative chiropractic and functional medicine lead, aligning spine and joint function, autonomic balance, and rehabilitation with modern cardiometabolic therapies.

How we integrate care:

• Medical oversight and safety: Advanced therapies (SGLT2 inhibitors, GLP-1 RAs, ARNI/ACEI/ARB, beta-blockers, MRAs) are initiated and monitored by Dr. Cardenas to ensure safety and adherence to guidelines.
• Chiropractic and rehabilitation: I optimize gait, posture, thoracic mobility, and neuromuscular control to improve venous return, respiratory mechanics, and autonomic balance—critical for heart failure and diabetes.
• Functional medicine: We evaluate systemic inflammation, visceral adiposity, sleep and circadian health, gut-metabolic signals, and nutrition to reduce cardiometabolic load.
• Personal injury care: Coordinated management reduces pain barriers, improves adherence to activity plans, and supports overall outcomes.

Clinical observations from my work, including case patterns and outcomes, are shared at:

• https://sciatica.clinic/
• https://www.linkedin.com/in/dralexjimenez/

The Cardio-Metabolic Interlock: Why Diabetes Drives Heart Failure

Type 2 diabetes and heart failure are biologically intertwined. Diabetes doesn’t just raise atherosclerosis risk; it independently drives heart failure through pathways beyond obstructive coronary disease.

Key physiologic sequence:

• Hyperglycemia → Insulin resistance → Hyperinsulinemia
• Chronic inflammation from visceral and epicardial adiposity
• Dyslipidemia and endothelial dysfunction causing arterial stiffness and microvascular compromise
• Neurohormonal activation (RAAS and sympathetic overdrive) raising preload/afterload
• Myocardial remodeling (fibrosis, hypertrophy, impaired energetics)
• Diabetic cardiomyopathy: structural and functional changes independent of ischemia

Why this matters:

• Inflammation and oxidative stress stiffen vessels and myocardium.
• Endothelial dysfunction reduces coronary microvascular flow, worsening perfusion.
• Neurohormonal activation promotes remodeling and fluid retention.
• Energetic deficits in cardiomyocytes lower contractile efficiency and relaxation.

These mechanisms explain the excess risk of both HFpEF and HFrEF in diabetes and guide why therapies that modulate renal sodium handling, energetics, and inflammation deliver outsized benefits (Heidenreich et al., 2022).

Heart Failure Phenotypes and Treatment Targets

Heart failure is categorized by left ventricular ejection fraction (LVEF), reflecting distinct physiologies:

• Heart Failure with Preserved Ejection Fraction (HFpEF; LVEF ≥50%)

• • Dominant diastolic dysfunction with stiff ventricles and impaired relaxation
  • Often linked to obesity, type 2 diabetes, hypertension, AF, CKD
  • Driven by microvascular dysfunction, interstitial fibrosis, and systemic inflammation
  • Care priorities: meticulous decongestion, risk-factor control, weight and sleep optimization, and SGLT2 inhibitors to reduce HF events (Anker et al., 2021)

• Heart Failure with Reduced Ejection Fraction (HFrEF; LVEF <40%)

• • Primarily systolic dysfunction with reduced contractility and eccentric remodeling
  • Often post-ischemic but may evolve from HFpEF
  • Care priorities: quadruple therapy (ARNI/ACEI/ARB, evidence-based beta-blocker, MRA, SGLT2 inhibitor), device consideration, and inflammation reduction (McMurray et al., 2019; Packer et al., 2020)

Converging theme: Controlling glycemia, adiposity (including epicardial fat), sodium balance, and inflammatory tone alters the remodeling trajectory.

SGLT2 Inhibitors: A Heart-Kidney-Metabolism Bridge

SGLT2 inhibitors act in the proximal convoluted tubule, reducing glucose and sodium reabsorption. Their system-level benefits connect heart, kidney, and metabolism:

Mechanisms that matter:

• Natriuresis and osmotic diuresis: reduce preload and interstitial congestion with less neurohormonal activation than loop diuretics
• Tubuloglomerular feedback restoration: lower intraglomerular pressure, slowing CKD progression
• Energetic rebalancing: mild ketosis provides a more efficient fuel for the failing heart
• Anti-inflammatory and anti-fibrotic effects: attenuate oxidative stress and fibrotic signaling
• Endothelial improvement and plaque stabilization
• Weight and blood pressure reduction: modest, synergistic gains for HF goals

Clinical evidence:

• HFrEF: Empagliflozin and dapagliflozin reduce CV death/HF hospitalizations—even without diabetes (DAPA-HF; EMPEROR-Reduced) (McMurray et al., 2019; Packer et al., 2020).
• HFpEF: Empagliflozin lowers HF hospitalizations across LVEF >40% (EMPEROR-Preserved) (Anker et al., 2021).
• CKD: Empagliflozin slows CKD progression and reduces HF events (EMPA-KIDNEY); canagliflozin improves kidney and CV outcomes in T2D with CKD (CREDENCE) (The EMPA-KIDNEY Collaborative Group, 2022; Perkovic et al., 2019).
• Acute HF: In-hospital initiation is feasible and beneficial (EMPULSE) (Voors et al., 2022).

Safety and application:

• Effective down to eGFR ~20 mL/min/1.73 m² for several agents; monitor volume status, renal function, and euglycemic DKA risk in insulin-deficient or acutely ill patients (Heerspink et al., 2020).

GLP-1 Receptor Agonists: Weight, Vascular Protection, and Inflammation Control

GLP-1 receptor agonists extend beyond glucose lowering to address atherosclerosis, weight, and inflammation.

Outcome highlights:

• Reduced MACE in high-risk T2D: LEADER (liraglutide), SUSTAIN-6 and PIONEER (semaglutide), REWIND (dulaglutide) (Marso et al., 2016; Husain et al., 2019; Gerstein et al., 2019).
• Benefits in obesity without diabetes: SELECT shows ~20% reduction in composite CV outcomes with semaglutide, including stroke signals; STEP trials demonstrate 15–16% weight loss with cardiometabolic improvements (Wilding et al., 2021; Lincoff et al., 2023; Wadden et al., 2024).
• Functional gains in HFpEF with obesity: Semaglutide improves quality of life and exercise capacity (STEP HFpEF).

Mechanistic rationale:

• Glucose-dependent insulin effects and glucagon suppression reduce postprandial stress.
• Endothelial stabilization and improvements in plaque biology—less macrophage infiltration and better nitric oxide bioavailability (Nystrom et al., 2018).
• Inflammation downshift: lower IL-6, TNF-α, and CRP (Bethel & Patel, 2016).
• Appetite and gastric emptying effects drive weight loss, reducing epicardial fat and systemic cytokines.

Safety:

• Low risk of hypoglycemia due to nutrient-responsive action; titrate to overcome GI symptoms.

Translating Evidence Into Practice: How We Choose and Combine Therapies

Guideline alignment:

• Established ASCVD: Prioritize GLP-1 RAs for MACE reduction; SGLT2s complement (ADA, 2024).
• Heart failure or CKD: Prioritize SGLT2 inhibitors; add GLP-1 RAs for weight and vascular benefits (Heidenreich et al., 2022).
• Combination therapy: Common and supported for high-risk patients, targeting HF risk, CKD progression, and atherosclerotic events.

Clinical considerations:

• Replace sulfonylureas to avoid hypoglycemia without CV benefit.
• Avoid DPP-4 inhibitors when GLP-1 RAs are available, given superior outcomes in weight and CV protection.

---

Optimizing Your Wellness- Video

---

Case Integration: Transition After MI With HFrEF and Type 2 Diabetes

A typical scenario from our practice:

• A patient post-MI with new HFrEF on metformin, a sulfonylurea, and a DPP-4 inhibitor.

Reasoned plan:

• Remove the sulfonylurea to reduce hypoglycemia risk.
• Stop the DPP-4 inhibitor and add a GLP-1 RA (e.g., semaglutide or liraglutide) to reduce MACE and promote weight loss.
• Add an SGLT2 inhibitor (empagliflozin or dapagliflozin) to reduce the risk of HF hospitalization and protect the kidneys.
• Maintain metformin if tolerated; consider combination formulations to reduce pill burden.
• Initiate the four pillars of HFrEF therapy: ARNI (or ACEI/ARB), a proven beta-blocker, an MRA, and an SGLT2 inhibitor, titrated carefully.

Why this works:

• We simultaneously relieve hemodynamic stress, optimize fuel handling, dampen inflammation, and stabilize vascular risk—each pillar addressing a distinct pathophysiologic domain (McMurray et al., 2019; Packer et al., 2020; ADA, 2024).

Off-Label Nuance: Type 1 Diabetes, CKD, and Heart Failure

In selected type 1 diabetes patients (including LADA) with obesity, CKD, and HF features, off-label use of SGLT2 inhibitors and GLP-1 RAs can be discussed under strict safety protocols:

• SGLT2 inhibitors: lower intraglomerular pressure, reduce HF hospitalizations, and improve natriuresis; in type 1, they can reduce insulin requirements but increase the risk of euglycemic DKA. With sick-day rules and ketone monitoring, some international practices use them carefully (Heerspink et al., 2020; Zelniker & Braunwald, 2018).
• GLP-1 RAs: potent weight-loss and atheroprotective effects support cardiometabolic risk reduction even when endogenous insulin is absent; used off-label in type 1 diabetes with informed consent (Marso et al., 2016; Gerstein et al., 2019).

Safety playbook:

• Do not stop basal insulin during illness; provide ketone strips and instructions.
• Hold SGLT2s during acute GI illness or poor intake; reassess upon recovery (Fadini et al., 2017).
• Monitor potassium and renal function when adding MRAs and SGLT2s; expect a small dip in eGFR that typically stabilizes by 3–4 weeks (Heerspink et al., 2020).

Access strategies:

• Use obesity indications for GLP-1 RAs where BMI criteria are met.
• Use HF and CKD indications for SGLT2s independent of diabetes.
• Explore manufacturer assistance and competitive cash programs to ensure continuity.

Integrative Chiropractic, Rehabilitation, and Functional Medicine: Making Medical Therapy Work Better

How integrative chiropractic care fits:

• Posture and thoracic mobility: Restoring ribcage and diaphragmatic motion optimizes venous return and reduces cardiac workload during exertion.
• Autonomic balance: Manual therapy, targeted breathing, and neuromuscular re-education reduce sympathetic overdrive, lowering resting heart rate and blood pressure variability.
• Gait and load management: Biomechanical correction reduces energy cost of movement, improving exercise tolerance in obesity and heart failure.

Functional medicine integration:

• Visceral adiposity reduction: Emphasis on nutrient-dense eating, adequate protein, fiber-rich patterns, and circadian alignment to reduce IL-6 and TNF-α
• Endothelial support: Omega-3s, polyphenols, and nitric-oxide–supportive foods (leafy greens, beets) complement pharmacotherapy.
• Gut-metabolic axis: Managing dysbiosis and postprandial spikes improves incretin dynamics and reduces endotoxemia.
• Rehabilitation protocols: Graded aerobic and resistance training improve VO2, insulin sensitivity, and mood; we dose carefully to avoid exacerbating HF symptoms.

Clinical observations:

• In my practice, combining GLP-1–driven weight loss with thoracic mobility, diaphragmatic training, and graded rehab consistently improves dyspnea and stamina, especially in HFpEF with obesity, echoing STEP HFpEF signals.
• In sciatica and biomechanical pain populations, reducing pain enhances sleep and autonomic balance, improving adherence to cardioprotective activities—patterns I share at sciatica.clinic and on my LinkedIn profile.

Practical Protocols: Implementation, Monitoring, and Safety

Initiation steps:

• Baseline labs: A1C, fasting lipid panel, NT-proBNP, BMP (renal function), LFTs, CRP.
• Vitals and function: Sitting/standing BP, weight and waist circumference, 6-minute walk, symptom scores (e.g., KCCQ).
• Medication plan: Select a GLP-1 RA and an SGLT2 agent based on comorbidities; titrate the GLP-1 RA slowly to mitigate GI effects.

Follow-up schedule:

• 2–4 weeks: GI tolerance, hydration, BP trends, weight trajectory.
• 8–12 weeks: Lipids, CRP, renal function; adjust HF pillars and rehab intensity.
• 3–6 months: Reassess MACE markers, quality-of-life scores, exercise capacity; refine nutrition and autonomic training.

Safety considerations:

• GLP-1 RAs: Manage GI upset with titration and meal pacing; rare pancreatitis—evaluate abdominal symptoms promptly.
• SGLT2 inhibitors: Watch for euglycemic DKA in high-risk contexts, genital mycotic infections, and volume shifts; enforce sick-day rules.
• Heart failure therapies: Titrate ARNI/ACEI/ARB and beta-blocker with BP/renal monitoring; add MRA with potassium checks.

Modern guidance on sodium and fluids:

• Avoid rigid fluid restriction in stable HF; extreme sodium restriction can harm nutrition and quality of life. With ARNI, MRA, and SGLT2 natriuresis, we guide patients to follow thirst cues, maintain adequate protein, and use daily weights to adjust diuretics under physician oversight.

Broader organ protection:

• Sleep apnea screening: Treating OSA improves BP, glycemic variability, and sympathetic tone (Patel & Redline, 2018).
• Liver health: Assess NAFLD/NASH risk via FIB-4/elastography; GLP-1–driven weight loss reduces hepatic steatosis and systemic inflammation (Armstrong et al., 2016).
• Frailty safeguards: For older adults on SGLT2s, monitor muscle mass, ensure adequate protein intake, and prioritize resistance training.

Bringing It Together: A Patient-Centered Care Map

• Phenotype heart failure: Distinguish HFpEF vs. HFrEF; assess CKD and ASCVD risks.
• Select mechanisms-matched therapies:

• HF and CKD risk → prioritize SGLT2 inhibitor.
• ASCVD and obesity-driven inflammation → prioritize GLP-1 RA.
• HFrEF → ensure quadruple therapy and rehab pacing.

• Integrate chiropractic and rehabilitative strategies to restore movement, reduce sympathetic tone, and support endothelial health.
• Monitor closely with shared medical-chiropractic oversight for safety and sustained progress.

This collaborative approach helps patients move, breathe, and live better while reducing hospitalizations, protecting kidneys, and improving long-term cardiovascular outcomes.

References

• EMPEROR-Reduced: Empagliflozin in HFrEF (Packer, M. et al., 2020). New England Journal of Medicine.
• DAPA-HF: Dapagliflozin in HFrEF (McMurray, J. J. V., et al., 2019). New England Journal of Medicine.
• EMPEROR-Preserved: Empagliflozin in HFpEF (Anker, S. D., et al., 2021). New England Journal of Medicine.
• EMPULSE: Empagliflozin in acute heart failure (Voors, A. A., et al., 2022). Nature Medicine.
• EMPA-KIDNEY: Empagliflozin in CKD (The EMPA-KIDNEY Collaborative Group, 2022). New England Journal of Medicine.
• CREDENCE: Canagliflozin in T2D with CKD (Perkovic, V. et al., 2019). New England Journal of Medicine.
• ADA Standards of Medical Care in Diabetes—2024 (ADA Professional Practice Committee, 2024). Diabetes Care.
• 2022/2023 AHA/ACC/HFSA Heart Failure Guidelines (Heidenreich, P. A., et al., 2022). Circulation.
• Cardiovascular outcomes with liraglutide (LEADER) (Marso, S. P., et al., 2016). New England Journal of Medicine.
• Oral semaglutide cardiovascular outcomes (PIONEER) (Husain, M. et al., 2019). New England Journal of Medicine.
• Dulaglutide cardiovascular outcomes (REWIND) (Gerstein, H. C., et al., 2019). The Lancet.
• Semaglutide outcomes in obesity without diabetes (SELECT) (Lincoff, A. M., et al., 2023). New England Journal of Medicine.
• STEP trials: Semaglutide 2.4 mg and weight loss (Wilding, J. P. H., et al., 2021). New England Journal of Medicine.
• Mechanisms and significance of SGLT2 in HF (Ferrannini, E. et al., 2016). Diabetes Care.
• GLP-1 RAs and endothelial function (Nystrom, T. et al., 2018). Cardiovascular Diabetology.
• GLP-1 RAs: Inflammation and CV effects (Bethel, M. A., & Patel, R. A., 2016). Diabetologia.
• SGLT2 inhibitors and renal/hemodynamic mechanisms (Heerspink, H. J. L., et al., 2020). New England Journal of Medicine.
• SGLT2 inhibitors, CV and renal benefits overview (Zelniker, T. A., & Braunwald, E., 2018). Circulation Research.
• SGLT2 inhibitors and the risk of euglycemic ketoacidosis (Fadini, G. P., et al., 2017). Diabetes Care.
• High-intensity statins and secondary prevention (Grundy, S. M., et al., 2019). Journal of the American College of Cardiology.
• Finerenone in diabetic CKD (Butler, J., et al., 2021). New England Journal of Medicine.
• Mediterranean diet and CV prevention (Estruch, R. et al., 2018). New England Journal of Medicine.
• GLP-1 RAs in NAFLD/NASH (Armstrong, M. J., et al., 2016). Gut.
• OSA treatment and cardiometabolic outcomes (Patel, S. R., & Redline, S., 2018). JAMA.

SEO tags: heart failure, HFrEF, HFpEF, type 2 diabetes, type 1 diabetes LADA, SGLT2 inhibitors, GLP-1 receptor agonists, EMPEROR-Reduced, DAPA-HF, EMPEROR-Preserved, EMPA-KIDNEY, CREDENCE, EMPULSE, LEADER, REWIND, SELECT, STEP, integrative chiropractic care, functional medicine, internal medicine collaboration, epicardial adipose tissue, diabetic cardiomyopathy, renal protection, autonomic balance, thoracic mobility, diaphragmatic training, El Paso Injury Medical Clinic, Mission Plaza Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, Dr. Alexander Jimenez DC, euglycemic DKA, sodium guidance, cardiac rehab, obesity and cardiometabolic risk, endothelial function, plaque stabilization, sciatica clinic, rehabilitation protocols